

AMENDMENTS TO THE SPECIFICATION:

Please enter into the specification the attached paper copy of the substitute Sequence Listing which includes 17 pages and provides sequences identified as SEQ ID NO:s 1-19.

On page 1, the title of the invention is amended to read as follows:

~~Apo-2 Receptor~~ Inducing Apoptosis Using anti-Apo-2 Antibodies

On page 1, under the title of the invention, in the paragraph on lines 10-14, the text is amended to read as follows:

-- This application is a divisional application of non-provisional application serial no. 09/079,029, ~~now pending~~ filed May 14, 1998, issued as US Patent No. 6,342,369, claiming priority under Section 119(e) to provisional application number 60/046,615 filed May 15, 1997 and provisional application number 60/074,119 filed February 9, 1998, the contents of which are hereby incorporated by reference. --

On page 11, in the paragraphs on lines 15-23, the text is amended as follows:

--- Figure 2A shows the derived amino acid sequence of a native sequence human Apo-2 (SEQ ID NO:1) - the putative signal sequence is underlined, the putative transmembrane domain is boxed, and the putative death domain sequence is dash underlined. The cysteines of the two cysteine-rich domains are individually underlined.

Figure 2B shows an alignment and comparison of the death domain sequences of native sequence human Apo-2 (SEQ ID NO:15), DR4 (SEQ ID NO:16), Apo-3/DR3 (SEQ ID NO:17), TNFR1 (SEQ ID NO:18), and Fas/Apo-1 (CD95) (SEQ ID NO:19). Asterisks indicate residues that are essential for death signaling by TNFR1 [Tartaglia et al., supra]. ---

On page 14, in the paragraph on lines 1-5, the text is amended as follows:

---- Figure 16 shows the single chain antibody (scFv) fragments referred to as 16E2 (SEQ ID NO:9), 20E6 (SEQ ID NO:10), and 24C4 (SEQ ID NO:11), with the respective amino acid sequences for signal sequence and the heavy and light chain CDR regions identified (CDR1, CDR2, and CDR3 regions are underlined). ----